Cabozantinib with temozolomide showed a meaningful clinical benefit and could potentially be a viable treatment option for patients with unresectable or metastatic leiomyosarcoma. Treatment was tolerable and did not reveal any new safety signals.
[Articles] Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial
The Lancet Oncology | | Varun Monga, Scott Okuno, Brian Van Tine, Seth M Pollack, Mia Weiss, Angela Hirbe, Pedro Viveiros, Brian Schulte, Steven Attia, Brittany Siontis, Mohammad M Milhem, John A Charlson, Steven Robinson, Oluwatimilehin Okunowo, Paul Frankel, Doni Woo, Janet Yoon, Mark Agulnik
Topics: blood-cancer, sarcoma, clinical-trials, research